Reduction in breast cancer mortality due to the introduction of mass screening in the Netherlands: Comparison with the United Kingdom

Journal of Medical Screening

Volumn 6, Issue 1, 1999, Pages 30-34

  Van Den Akker Van Marle, Elske ^a   De Koning, Harry ^a   Boer, Rob ^a   Van Der Maas, Paul ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Breast cancer; Mortality

Indexed keywords

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; COMPARATIVE STUDY; EARLY DIAGNOSIS; MAMMOGRAPHY; MASS SCREENING; NETHERLANDS; RISK ASSESSMENT; UNITED KINGDOM;

EID: 0032964275     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1136/jms.6.1.30     Document Type: Article

References (15)

1. Tornberg S, Carstensen J, Hakulinen T, et al. Evaluation of the effect on breast cancer mortality of population based mammography screening programmes. J Med Screen 1994;1:184-7.
2. Quinn M, Allen E. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. BMJ 1995;311:1391-5.
3. Chu KC, Tarone RE, Kessler LG, et al. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88:1571-9.
4. Hakama M, Pukkala E, Heikkila M, et al. Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ 1997;314: 864-7.
5. de Koning HJ, Boer R, Warmerdam PG, et al. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995;87:1217-23.
6. van Oortmarssen GJ, Habbema JD, van der Maas PJ, et al. A model for breast cancer screening. Cancer 1990;66:1601-12.
7. de Koning HJ, Fracheboud J, Boer R, et al. Nation-wide breast cancer screening in the Netherlands: support for breast-cancer mortality reduction. National Evaluation Team for Breast Cancer Screening (NETB). Int J Cancer 1995;60:777-80.
8. de Koning HJ, van Ineveld BM, van Oortmarssen GJ, et al. Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int J Cancer 1991;49:531-7.
9. Boer R, de Koning HJ, Threlfall A, et al. Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ 1998;317:376-9.
10. Chamberlain J, Moss S, Kirkpatrick A, et al. National Health Service breast screening programme results for 1991-2. BMJ 1993;307:353-6.
11. Waterhouse J, Muir C, Correa P, et al. Cancer incidence in five continents. Vol III. Lyon: IARC Scienific Publications, 1976: No 15.
12. Netherlands Central Bureau of Statistics. Death by causes of death, age and gender 1989-1996. Netherlands Central Bureau of Statistics. (Published annually.)
13. Smith C, Kricker A, Armstrong B. Breast cancer mortality trends in Australia: 1921 to 1994. Med J Aust 1998;168:11-14.
14. Day N, McCann J, Camilleri-Ferrante C, et al. Monitoring interval cancers in breast screening programmes: the East Anglian experience. Quality Assurance Management Group of the East Anglian Breast Screening Programme. J Med Screen 1995;2:180-5.
15. Collins S, Woodman C, Threlfall A, et al. Survival rates from interval cancer in NHS breast screening programme. BMJ 1998;316:832-3.